Neurotoxicity of Human Immunodeficiency Virus-1: Viral Proteins and Axonal Transport

被引:54
|
作者
Mocchetti, Italo [1 ]
Bachis, Alessia [1 ]
Avdoshina, Valeriya [1 ]
机构
[1] Georgetown Univ, Dept Neurosci, Med Ctr, Washington, DC 20057 USA
关键词
Autophagy; BDNF; Chemokine receptors; gp120; HIV-1-associated dementia; Tat; CHEMOKINE RECEPTOR CXCR4; HIV-ASSOCIATED DEMENTIA; CENTRAL-NERVOUS-SYSTEM; D-ASPARTATE RECEPTOR; NEURONAL CELL-DEATH; TYPE-1 TAT PROTEIN; NEUROTROPHIC FACTOR; ANTIRETROVIRAL THERAPY; RAT STRIATUM; IN-VIVO;
D O I
10.1007/s12640-011-9279-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Human immunodeficiency virus-1 (HIV) infection of the central nervous system may cause a neurological syndrome termed HIV-associated neurocognitive disorder (HAND) which includes minor neurocognitive disorders or a more severe form of motor and cognitive impairments. Although treatment with highly active antiretroviral agents decreases the load of HIV in the brain, the prevalence of mild forms of HAND is actually increased due to longer life. Therefore, adjunctive and combined therapies must be developed to prevent and perhaps reverse the neurologic deficits observed in individuals with HAND. Key to developing effective therapies is a better understanding of the molecular and cellular mechanisms by which the virus causes this disorder. A number of HIV proteins has been shown to be released from HIV-infected cells. Moreover, these proteins have been shown to possess neurotoxic properties. This review describes new evidence of a direct interaction of the HIV protein gp120 with neurons, which might play a role in the etiopathology of HAND.
引用
收藏
页码:79 / 89
页数:11
相关论文
共 50 条
  • [21] Viral Escape in the Central Nervous System with Multidrug-Resistant Human Immunodeficiency Virus-1
    Beguelin, C.
    Vazquez, M.
    Bertschi, M.
    Yerly, S.
    de Jong, D.
    Gutbrod, K.
    Rauch, A.
    Cusini, A.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2016, 3 (01):
  • [22] Zidovudine treatment prevents vertical transmission of human immunodeficiency virus-1 independently of viral load
    Arias, RA
    Gurbindo, MD
    Miralles, P
    Segovia, P
    Fernández-Cruz, E
    Muñoz-Fernández, MA
    [J]. ACTA PAEDIATRICA, 1998, 87 (11) : 1208 - 1209
  • [23] Retrotransposition and senescence in mouse heart tissue by viral protein R of human immunodeficiency virus-1
    Ueno, Mikako
    Matsunaga, Akihiro
    Teratake, Yoichi
    Ishizaka, Yukihito
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2020, 114
  • [24] EXPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS-1 IN HUMAN COLONIC CELLS
    KAGNOFF, MF
    OMARY, MB
    DEGRANDPRE, LY
    ROEBUCK, KA
    RICHMAN, DD
    BRENNER, DA
    [J]. IMMUNOLOGIC RESEARCH, 1991, 10 (3-4) : 452 - 455
  • [25] Polycythemia in patients infected with human immunodeficiency virus-1
    Koduri, PR
    Sherer, R
    Teter, C
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2000, 64 (01) : 80 - 81
  • [26] Analysis of the human immunodeficiency virus-1 RNA packageome
    Eckwahl, Matthew J.
    Arnion, Helene
    Kharytonchyk, Siarhei
    Zang, Trinity
    Bieniasz, Paul D.
    Telesnitsky, Alice
    Wolin, Sandra L.
    [J]. RNA, 2016, 22 (08) : 1228 - 1238
  • [27] Group O human immunodeficiency virus-1 infections
    Jaffe, HW
    Schochetman, G
    [J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1998, 12 (01) : 39 - +
  • [28] Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1
    McPherson, Tristan D.
    Sobieszczyk, Magdalena E.
    Markowitz, Martin
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (04) : 413 - 420
  • [29] Finding a Cure for Human Immunodeficiency Virus-1 Infection
    Blankson, Joel N.
    Siliciano, Janet D.
    Siliciano, Robert F.
    [J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2014, 28 (04) : 633 - +
  • [30] Hydroxyurea to inhibit human immunodeficiency virus-1 replication
    Romanelli, F
    Pomeroy, C
    Smith, KM
    [J]. PHARMACOTHERAPY, 1999, 19 (02): : 196 - 204